Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1007/s40262-014-0230-6 http://scihub22266oqcxt.onion/10.1007/s40262-014-0230-6 C5677184!5677184 !25559342     free     free     free Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\25559342 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Clin+Pharmacokinet 2015 ; 54 (2 ): 147-66 Nephropedia Template TP {{tp|p=25559342 |t=2015. Clinical pharmacokinetics and pharmacodynamics of clopidogrel |pdf=|usr=}}{{25559342 }} gab.com Text Clinical pharmacokinetics and pharmacodynamics of clopidogrel JO: Clin Pharmacokinet http://www.kidney.de/pget.php?&tw=1&pmid=25559342 #FOAvip Acute coronary syndromes (ACS) remain life-threatening disorders, which are associated with high morbidity and mortality. Dual antiplatelet therapy with aspirin and clopidogrel has been shown to reduce cardiovascular events in patients with ACS. However, there is substantial inter-individual variability in the response to clopidogrel treatment, in addition to prolonged recovery of platelet reactivity as a result of irreversible binding to P2Y12 receptors. This high inter-individual variability in treatment response has primarily been associated with genetic polymorphisms in the genes encoding for cytochrome (CYP) 2C19, which affect the pharmacokinetics of clopidogrel. While the US Food and Drug Administration has issued a boxed warning for CYP2C19 poor metabolizers because of potentially reduced efficacy in these patients, results from multivariate analyses suggest that additional factors, including age, sex, obesity, concurrent diseases and drug-drug interactions, may all contribute to the overall between-subject variability in treatment response. However, the extent to which each of these factors contributes to the overall variability, and how they are interrelated, is currently unclear. The objective of this review article is to provide a comprehensive update on the different factors that influence the pharmacokinetics and pharmacodynamics of clopidogrel and how they mechanistically contribute to inter-individual differences in the response to clopidogrel treatment. Twit Text FOAVip Clinical pharmacokinetics and pharmacodynamics of clopidogrel ????Clin Pharmacokinet http://www.kidney.de/pget.php?&tw=1&pmid=25559342 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=25559342 #FOAvip English Wikipedia <ref>{{Cite pmid|25559342 }}</ref> Clinical pharmacokinetics and pharmacodynamics of clopidogrel #MMPMID25559342 Jiang XL ; Samant S ; Lesko LJ ; Schmidt S Clin Pharmacokinet 2015[Feb]; 54 (2 ): 147-66 PMID25559342 show ga Acute coronary syndromes (ACS) remain life-threatening disorders, which are associated with high morbidity and mortality. Dual antiplatelet therapy with aspirin and clopidogrel has been shown to reduce cardiovascular events in patients with ACS. However, there is substantial inter-individual variability in the response to clopidogrel treatment, in addition to prolonged recovery of platelet reactivity as a result of irreversible binding to P2Y12 receptors. This high inter-individual variability in treatment response has primarily been associated with genetic polymorphisms in the genes encoding for cytochrome (CYP) 2C19, which affect the pharmacokinetics of clopidogrel. While the US Food and Drug Administration has issued a boxed warning for CYP2C19 poor metabolizers because of potentially reduced efficacy in these patients, results from multivariate analyses suggest that additional factors, including age, sex, obesity, concurrent diseases and drug-drug interactions, may all contribute to the overall between-subject variability in treatment response. However, the extent to which each of these factors contributes to the overall variability, and how they are interrelated, is currently unclear. The objective of this review article is to provide a comprehensive update on the different factors that influence the pharmacokinetics and pharmacodynamics of clopidogrel and how they mechanistically contribute to inter-individual differences in the response to clopidogrel treatment. |Acute Coronary Syndrome/drug therapy/metabolism [MESH] |Clopidogrel [MESH] |Cytochrome P-450 CYP2C19/genetics/metabolism [MESH] |Dose-Response Relationship, Drug [MESH] |Humans [MESH] |Polymorphism, Genetic [MESH] |Precision Medicine [MESH] |Purinergic P2Y Receptor Antagonists/pharmacokinetics/pharmacology [MESH]Clinical pharmacokinetics and pharmacodynamics of clopidogrel (epmc).pdf DeepDyve Pubget Overpricing